Person: Cabello Olmo, Miriam
Loading...
Email Address
person.page.identifierURI
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
Cabello Olmo
First Name
Miriam
person.page.departamento
Ciencias de la Salud
person.page.instituteName
ORCID
0000-0001-5024-7675
person.page.upna
812113
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication Open Access New insights into immunotherapy strategies for treating autoimmune diabetes(MDPI, 2019) Cabello Olmo, Miriam; Araña Ciordia, Miriam; Radichev, Ilian; Smith, Paul; Huarte, Eduardo; Barajas Vélez, Miguel Ángel; Ciencias de la Salud; Osasun Zientziak; Gobierno de Navarra / Nafarroako GobernuaType 1 diabetes mellitus (T1D) is an autoimmune illness that affects millions of patients worldwide. The main characteristic of this disease is the destruction of pancreatic insulin-producing beta cells that occurs due to the aberrant activation of different immune effector cells. Currently, T1D is treated by lifelong administration of novel versions of insulin that have been developed recently; however, new approaches that could address the underlying mechanisms responsible for beta cell destruction have been extensively investigated. The strategies based on immunotherapies have recently been incorporated into a panel of existing treatments for T1D, in order to block T-cell responses against beta cell antigens that are very common during the onset and development of T1D. However, a complete preservation of beta cell mass as well as insulin independency is still elusive. As a result, there is no existing T1D targeted immunotherapy able to replace standard insulin administration. Presently, a number of novel therapy strategies are pursuing the goals of beta cell protection and normoglycemia. In the present review we explore the current state of immunotherapy in T1D by highlighting the most important studies in this field, and envision novel strategies that could be used to treat T1D in the future.Publication Open Access Study of the stability of a plant-based fermented product and its effect in a murine model of type II diabetes(2020) Cabello Olmo, Miriam; Barajas Vélez, Miguel Ángel; Araña Ciordia, Miriam; Ciencias de la Salud; Osasun Zientziak; Gobierno de Navarra / Nafarroako GobernuaEsta tesis se basa en tres publicaciones científicas. En primer lugar, analizamos el efecto de la suplementación con Probisan® en la rata Zucker Diabetic Fatty, un modelo animal experimental de diabetes tipo 2, en un estudio que duró 31 semanas (Estudio 1). Al final del estudio observamos que la administración de Probisan® en este modelo animal no previno el desarrollo de diabetes tipo 2 aunque si retrasó el inicio de la enfermedad. Además de ello, pudimos confirmar que la suplementación con Probisan® fue favorable porque disminuyó las complicaciones y molestias derivadas de la diabetes, mejorando la salud de los animales suplementados e incrementando su esperanza de vida. Presuponemos que dicha protección se obtuvo mediante la modulación de la microbiota gastrointestinal. En cualquier caso, nuestro estudio presenta ciertas limitaciones y se requiere de más estudios para esclarecer el tema. En segundo lugar, actualizamos el conocimiento sobre el papel de la microbiota gastrointestinal en la patogénesis de la diabetes tipo 1, otra forma de diabetes mellitus (Estudio 2). Se trata de un tema de suma importancia ya que la diabetes tipo 1 es una enfermedad incurable y existe una gran heterogeneidad en la respuesta de los pacientes frente a los tratamientos, lo que dificulta el desarrollo de tratamientos efectivos para la mayoría de enfermos. Para ello realizamos una revisión narrativa sobre las terapias emergentes para tratar la enfermedad. Particularmente, nos centramos en aquellas estrategias basadas en la inmunoterapia, y en una de las secciones del trabajo profundizamos sobre el papel de la microbiota como nuevo enfoque para tratar la enfermedad. Este estudio nos aportó una perspectiva más amplia para comprender mejor la implicación de los microorganismos intestinales en la diabetes mellitus. Además, nos permitió explorar las posibles estrategias terapéuticas para abordar la diabetes tipo 1 mediante cambios en la ecología microbiana intestinal, tanto a nivel estructural como funcional. Por último, con el objetivo de conocer mejor Probisan® y su comportamiento en el tiempo, quisimos evaluar los cambios que tienen lugar en el producto durante su almacenamiento (Estudio 3). Para analizar las propiedades fisicoquímicas y microbiológicas del producto a lo largo del tiempo realizamos un estudio de campo en el cual Probisan® estuvo expuesto a condiciones de almacenamiento simuladas durante su vida útil (1 año). Para ello se prepararon pequeños sacos con Probisan® (150 g de producto) que fueron almacenados en ocho condiciones diferentes [cuatro temperaturas de almacenamiento (-20 ºC, 4 ºC, 22 ºC and 37 ºC) y dos tipos de envasado (envasado normal y envasado al vacío)]. El pH, la humedad y los recuentos de bacterias totales, bacterias lácticas y levaduras fueron determinados en cada tiempo de muestreo (0, 1, 3, 6 y 12 meses de almacenamiento). Estábamos particularmente interesados en el estudio de la viabilidad microbiana ya que hipotetizamos que los microorganismos vivos podrían jugar un papel clave en los efectos beneficiosos de Probisan®. Al final del estudio pudimos concluir que la carga microbiana de Probisan® se ve afectada negativamente en todas las condiciones estudiadas, y que dicho efecto se intensifica con el tiempo. Nuestros resultados revelaron que, de acuerdo con nuestra hipótesis de partida, el almacenamiento a baja temperatura (-20 ºC y 4 ºC) protege mejor la viabilidad de los microorganismos en Probisan® en comparación con el almacenamiento a temperatura ambiente (22 ºC) o alta temperatura (37 ºC). Por otro lado, no encontramos diferencias importantes entre las dos formas de envasado en los parámetros de estudio, descartándose por tanto el envasado al vacío como posible estrategia para preservar la carga de microorganismos vivos en Probisan®. No obstante, futuros estudios podrían valorar otras formas alternativas de envasado.Publication Open Access Antidiabetic effects of Pediococcus acidilactici pA1c on HFD-induced mice(MDPI, 2022) Cabello Olmo, Miriam; Oneca Agurruza, María; Pajares Villandiego, María Josefa; Jiménez, Maddalen; Ayo, Josune; Encío Martínez, Ignacio; Barajas Vélez, Miguel Ángel; Araña Ciordia, Miriam; Ciencias de la Salud; Osasun Zientziak; Gobierno de Navarra / Nafarroako Gobernua, 0011-1365-2020-000086Prediabetes (PreD), which is associated with impaired glucose tolerance and fasting blood glucose, is a potential risk factor for type 2 diabetes mellitus (T2D). Growing evidence suggests the role of the gastrointestinal microbiota in both PreD and T2D, which opens the possibility for a novel nutritional approach, based on probiotics, for improving glucose regulation and delaying disease progression of PreD to T2D. In this light, the present study aimed to assess the antidiabetic properties of Pediococcus acidilactici (pA1c) in a murine model of high-fat diet (HFD)-induced T2D. For that purpose, C57BL/6 mice were given HFD enriched with either probiotic (1 × 1010 CFU/day) or placebo for 12 weeks. We determined body weight, fasting blood glucose, glucose tolerance, HOMA-IR and HOMA-β index, C-peptide, GLP-1, leptin, and lipid profile. We also measured hepatic gene expression (G6P, PEPCK, GCK, IL-1β, and IL-6) and examined pancreatic and intestinal histology (% of GLP-1+ cells, % of goblet cells and villus length). We found that pA1c supplementation significantly attenuated body weight gain, mitigated glucose dysregulation by reducing fasting blood glucose levels, glucose tolerance test, leptin levels, and insulin resistance, increased C-peptide and GLP-1 levels, enhanced pancreatic function, and improved intestinal histology. These findings indicate that pA1c improved HFD-induced T2D derived insulin resistance and intestinal histology, as well as protected from body weight increase. Together, our study proposes that pA1c may be a promising new dietary management strategy to improve metabolic disorders in PreD and T2D.Publication Open Access A fermented food product containing lactic acid bacteria protects ZDF rats from the development of type 2 diabetes(MDPI, 2019) Cabello Olmo, Miriam; Oneca Agurruza, María; Torre Hernández, Paloma; Sainz, Neira; Moreno Aliaga, María J.; Guruceaga, Elizabeth; Díaz, Jesús Vicente; Encío Martínez, Ignacio; Barajas Vélez, Miguel Ángel; Araña Ciordia, Miriam; Ciencias de la Salud; Osasun Zientziak; Ciencias; Zientziak; Gobierno de Navarra / Nafarroako GobernuaType 2 diabetes (T2D) is a complex metabolic disease, which involves a maintained hyperglycemia due to the development of an insulin resistance process. Among multiple risk factors, host intestinal microbiota has received increasing attention in T2D etiology and progression. In the present study, we have explored the effect of long-term supplementation with a non-dairy fermented food product (FFP) in Zucker Diabetic and Fatty (ZDF) rats T2D model. The supplementation with FFP induced an improvement in glucose homeostasis according to the results obtained from fasting blood glucose levels, glucose tolerance test, and pancreatic function. Importantly, a significantly reduced intestinal glucose absorption was found in the FFP-treated rats. Supplemented animals also showed a greater survival suggesting a better health status as a result of the FFP intake. Some dissimilarities have been observed in the gut microbiota population between control and FFP-treated rats, and interestingly a tendency for better cardiometabolic markers values was appreciated in this group. However, no significant differences were observed in body weight, body composition, or food intake between groups. These findings suggest that FFP induced gut microbiota modifications in ZDF rats that improved glucose metabolism and protected from T2D development.Publication Open Access Pediococcus acidilactici pA1c® improves the beneficial effects of metformin treatment in type 2 diabetes by controlling glycaemia and modulating intestinal microbiota(MDPI, 2023) Cabello Olmo, Miriam; Oneca Agurruza, María; Urtasun Alonso, Raquel; Pajares Villandiego, María Josefa; Goñi Irigoyen, Saioa; Riezu Boj, José I.; Milagro Yoldi, F. I.; Ayo, Josune; Encío Martínez, Ignacio; Barajas Vélez, Miguel Ángel; Araña Ciordia, Miriam; Ciencias de la Salud; Osasun ZientziakType 2 diabetes (T2D) is a complex metabolic disease, which involves maintained hyperglycemia, mainly due to the development of an insulin resistance process. Metformin administration is the most prescribed treatment for diabetic patients. In a previously published study, we demonstrated that Pediococcus acidilactici pA1c® (pA1c) protects from insulin resistance and body weight gain in HFD-induced diabetic mice. The present work aimed to evaluate the possible beneficial impact of a 16-week administration of pA1c, metformin, or the combination of pA1c and metformin in a T2D HFD-induced mice model. We found that the simultaneous administration of both products attenuated hyperglycemia, increased high-intensity insulin-positive areas in the pancreas and HOMA-β, decreased HOMA-IR and also provided more beneficial effects than metformin treatment (regarding HOMA-IR, serum C-peptide level, liver steatosis or hepatic Fasn expression), and pA1c treatment (regarding body weight or hepatic G6pase expression). The three treatments had a significant impact on fecal microbiota and led to differential composition of commensal bacterial populations. In conclusion, our findings suggest that P. acidilactici pA1c® administration improved metformin beneficial effects as a T2D treatment, and it would be a valuable therapeutic strategy to treat T2D.